CannaboTech

Botanical-based Medical Solutions

Health Tech & Life Sciences
Public on TASE on Jul, 2021

Company Overview

Snapshot

Founded in January 2019 by Moav Gafni and Yoav Rothler, CannaboTech operates with 1–10 employees. The company has raised $29 million across four funding rounds and went public on TASE in July 2021.

Business overview

CannaboTech develops advanced botanical-based medical solutions for conditions such as cancer, inflammation, and chronic pain. The company utilizes pure clinical and botanical qualities, combining cannabinoids and medicinal mushrooms to create its proprietary M²CBD formula. CannaboTech focuses on integrative care, preventive medicine, and botanical drugs, serving markets in Health Tech & Life Sciences, particularly in the Pharmaceuticals and Medical Cannabis sectors.

Strategic signal

In August 2024, news emerged that CannaboTech was heading towards a creditor settlement after raising 30 million ILS from the public. This development signals significant financial challenges for the company, indicating a need for restructuring and potentially impacting its future operational capabilities and investor confidence.

Company Intelligence Q&A

What is CannaboTech's core focus?
CannaboTech develops advanced medical solutions for cancer, inflammation, and chronic pain, utilizing a proprietary M²CBD formula that combines cannabinoids and medicinal mushrooms.
When did CannaboTech go public?
CannaboTech went public on TASE in July 2021.
What was a significant finding regarding CannaboTech's cancer treatments?
In March 2022, CannaboTech's "Integrative-Colon" products eliminated over 90% of colon cancer cells in a cell model experiment. Additionally, in April 2022, its botanical drug for pancreatic cancer demonstrated killing 100% of cancer cells without damaging healthy cells in a cell model.
What recent financial challenge has CannaboTech faced?
In August 2024, CannaboTech was reported to be heading towards a creditor settlement after raising 30 million ILS from the public.
What is CannaboTech's strategy for market expansion?
In January 2024, CannaboTech signed an agreement to establish three concept stores for its preventive medicine brand in Thailand, indicating a focus on expanding its presence in Southeast Asia.

External links